Author: Onnisa Nanegrungsunk (United States)
Co-authors: Guillaume Normand, Susan Bressler, Daniele Dolis, Carmel O’Reilly, John Seaman, Neil Bressler
Purpose
Following the COVID-19 pandemic in March 2020, clinic visits were limited to reduce the risk of COVID-19 exposure. Reliable and reproducible home visual acuity (VA) monitoring via smart phone applications (apps) have the potential to reduce the number and reliance on face-to-face clinical practice or clinical trial visits for neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) patients. Such apps might facilitate data collection between visits potentially providing further insights on treatment efficacy and/or natural history of ocular diseases. The FocalView app is a mobile medical research platform that includes a VA self-assessment module. The app presents a series of Landolt C rings in various orientations and sizes on a mobile device screen. By tapping a button on the screen corresponding to the gap in each ring, the app analyzes and measures VA. The purpose of this study is to determine the feasibility of the FocalView app for self-VA assessment at home and in the clinic after first introducing the app to the participant. Strategies to optimize testing frequency and accuracy of the VA obtained from the app, compared with standardized VA charts, will be pursued if the app is judged feasible to use in this way.
Setting/Venue
The study is an open, non-randomized, multi-site feasibility study conducted in 90 participants with nAMD or DME at several clinical sites. This study was designed starting in November 2019 and received IRB approval initially from Johns Hopkins University in October 2020. All participants provided written informed consent prior to enrollment. The study consists of three visits (Screening, V1; Baseline, V2; and End of Study, V3) matching three consecutive standard-care clinic visits of the participants for the management of nAMD or DME. Duration of study participation has been up to 180 days.
Methods
Patients with nAMD and DME, aged ≥18 years, VA better than 20/200 and receipt of intravitreal anti-vascular endothelial growth factor therapy within 4 to 24 weeks prior to V2 in their study eye were eligible. At V1, participants were assessed for best-corrected near VA (BCNVA) and best-corrected distance VA (BCDVA) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart or electronic-ETDRS, and instructed on how to use the app for monocular VA self-assessment with their near correction. Between V1 and V2 (screening period), participants were asked to use the app 3 times in a single day, at least weekly, in order to familiarize themselves with the app. Ability to use the app was assessed by an investigator’s direct observation at V1 and V2, and review of home usage data. Participants were excluded from further study participation if they were unable to perform the VA test with the app or follow the testing schedule. Participants who completed the screening period then continued using the app at different frequencies per session and days, according to pre-specified group allocations. For the preliminary analysis for this abstract, the feasibility to use the app during the screening period is reported using descriptive statistical analysis.
Results
From the preliminary results based on the initial 45 participants from the Johns Hopkins University clinical site, 38 (84%) had nAMD, mean (±SD) age was 73.3 (9.8) years and 25 (56%) were male. Forty-three participants (96%) could perform VA self-assessment in the clinic after the first introduction at V1 and 39 participants (87%) completed home VA self-assessment during the screening period consisting of at least one single day in which they performed three testing sessions. Among the 6 participants (13%) who did not successfully complete V1 or the screening period, 4 had nAMD, mean age (range) was 73.5 (45 to 88) years and 4 were male. Reasons for feasibility failure were as follows: 3 (7%) did not comply due to frequency of the testing schedule, 2 (4%) misunderstood the instructions, and 1 (2%) physically could not use the app.
Conlusions
To our knowledge, this is the first clinical study designed to identify the feasibility of successfully using a self-testing VA app at home and in the clinic in patients with nAMD or DME. Preliminary data showed the majority of participants could perform the VA self-assessment using the app without any physical or cognitive barrier, whether at home or in the clinic. Ability to adhere to the testing schedule may be challenging for some patients. Potential future analyses may include identification of optimal conditions in which to use the app and assess the agreement of the VA obtained from the app relative to in clinic VA measurements using standardized VA charts. Validating clinical use of this app relative to in clinic VA measurements among this population may facilitate home monitoring in these common diseases in the future.
Financial Disclosure
Onnisa Nanegrungsunk: None Guillaume Normand, John Seaman, and Guy Simpson: Employees of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Susan Bressler: received grants to Johns Hopkins University School of Medicine from Bayer, Biocon, Biogen, Boehringer-Ingleheim Pharma GmbH, Genentech (Roche), Mylan Inc, Notal Vision, Novartis and Regeneron; contract with Amgen as chair for DSMC Daniele Dolis and Georges Weissgerber: Employees of Novartis Pharma AG, Basel, Switzerland Carmel O’Reilly: Employee of Novartis Ireland Limited, Dublin, Ireland Lieve Convents: Employee of Novartis Pharma NV, Vilvoorde, Belgium Michael Elman: Grants from Allergan Pharmaceutical, Alimera Sciences, Apellis Pharmaceutical, Clover Therapeutics, Genentech Inc/F. Hoffmann La Roche, Graybug Vision, JAEB Center, Lowy Medical Research Institute, National Institutes of Health, Neurotech Pharmaceuticals, Inc., NGM Biopharmaceuticals Corporation, Notal Vision, Novartis Pharmaceuticals Corporation, Optos, The EMMES Company, YD Global Life Science Hani Salehi-Had: None Neil Bressler: received grants to Johns Hopkins University from Bayer, Biogen, Genentech (Roche), Novartis, Regeneron, Samsung Bioepis; contract with AMA as Editor in Chief of JAMA Ophthalmology
Comments
Additional Co-authors: 7. Georges Weissgerber 8. Guy Simpson 9. Lieve Convents 10. Michael Elman 11. Hani Salehi-Had